In vivo uses of aptamers selected against cell surface biomarkers for therapy and molecular imaging.
Nucleic acid Aptamers are ligands that are selected by a process of molecular evolution to bind with high affinities and specificities to a specific target. Recently, an increasing number of aptamers have been selected against biomarkers expressed at the surface of human cells or infectious pathogens. This class of targets, mostly proteins, is associated with several pathologies including cancer, inflammation and infection diseases. Several of these cell surface specific aptamers were tested in vivo as drugs or as targeting agents for nanocarriers, siRNA or contrast agents. Strikingly, they were used to develop a wide variety of new treatments or new approaches for molecular imaging and they were also able to improve current therapies such as chemotherapy, radiotherapy or immunotherapy. This review presents these different applications and the different studies conducted in vivo with this class of aptamers, predominantly in pre-clinical models.
CEA, DSV, I²BM, Service Hospitalier Frédéric Joliot (SHFJ), 4 place du général Leclerc, 91401 Orsay, France.
Agnes
A
Cibiel
Carine
C
Pestourie
Frédéric
F
Ducongé
D000818:Animals; D052157:Aptamers, Nucleotide / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D006801:Humans; D057054:Molecular Imaging / Q000379:methods*
D052157:Aptamers, Nucleotide; D015415:Biomarkers